Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 4D-150

            Therapeutic Area: Ophthalmology Product Name: 4D-150

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2021

            Details:

            Preclinical NHP studies of 4D-150 demonstrated significant efficacy in the laser-induced choroidal neovascularization (CNV) model, including complete suppression of CNV lesions at the lowest dose of 1E11 vg /eye.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sunitinib analog

            Therapeutic Area: Ophthalmology Product Name: D-4517

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 26, 2021

            Details:

            A single subcutaneous or oral dose of D-4517, a sunitinib analog, resulted in comparable or better inhibition of CNV to a single intravitreal (IVT) dose of aflibercept.